Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Durga Devi Perumal, Manikandan Krishnan & K.S. Lakshmi. (2022) Eco-friendly based stability-indicating RP-HPLC technique for the determination of escitalopram and etizolam by employing QbD approach. Green Chemistry Letters and Reviews 15:3, pages 671-682.
Read now
Read now
Kaida Jiang, Lingjiang Li, Xueyi Wang, Maosheng Fang, Jianfei Shi, Qiuyun Cao, Jincai He, Jinan Wang, Weihao Tan & Cuili Hu. (2017) Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population. Neuropsychiatric Disease and Treatment 13, pages 515-526.
Read now
Read now
Daniel Souery, Raffaella Calati, Konstantinos Papageorgiou, Alzbeta Juven-Wetzler, Joël Gailledreau, David Modavi, Othman Sentissi, William Pitchot, George N. Papadimitriou, Dimitris Dikeos, Stuart Montgomery, Siegfried Kasper, Joseph Zohar, Alessandro Serretti & Julien Mendlewicz. (2015) What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. The World Journal of Biological Psychiatry 16:7, pages 472-482.
Read now
Read now
Devin Pastoor & Joga Gobburu. (2014) Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opinion on Drug Metabolism & Toxicology 10:1, pages 121-128.
Read now
Read now
Articles from other publishers (40)
Paula C. Zimbrean, Sarah R. Andrews, Filza Hussain, Marian Fireman, Kristin Kuntz, Shehzad K. Niazi, Scott A. Simpson, Thomas Soeprono, Gerald Scott Winder & Sheila G. Jowsey-Gregoire. (2023) ACLP Best Practice Guidance: Evaluation and Treatment of Depression in Solid Organ Transplant Recipients. Journal of the Academy of Consultation-Liaison Psychiatry 64:4, pages 357-370.
Crossref
Crossref
Lena Hoffmann, Jörg Breitkreutz & Julian Quodbach. (2023) Investigation of the degradation and in-situ amorphization of the enantiomeric drug escitalopram oxalate during Fused Deposition Modeling (FDM) 3D printing. European Journal of Pharmaceutical Sciences 185, pages 106423.
Crossref
Crossref
Zhishuo Wang, Chenghua Yan, Qizhen Du, Yuying Huang, Xuezhen Li, Dan Zeng, Ruizhi Mao, Rama Krishna Gurram, Shipeng Cheng, Wangpeng Gu, Lin Zhu, Weiguo Fan, Liyan Ma, Zhiyang Ling, Ju Qiu, Dangsheng Li, Enmei Liu, Yaguang Zhang, Yiru Fang, Jinfang Zhu & Bing Sun. (2023) HTR2A agonists play a therapeutic role by restricting ILC2 activation in papain-induced lung inflammation. Cellular & Molecular Immunology 20:4, pages 404-418.
Crossref
Crossref
Seçkin Engin, Elif Nur Barut, Yasemin Erac, Suat Sari & Mine Kadioglu. (2023) The inhibitory effect of escitalopram on mouse detrusor contractility: The role of L-type calcium channels. Toxicology and Applied Pharmacology 461, pages 116408.
Crossref
Crossref
Vishal Bhatia, Ashwani K. Dhingra, Bhawna Chopra & Kumar Guarve. (2023) A Review of Clinical Studies Assessing the Therapeutic Efficacy of
Escitalopram: A Step Towards Development. CNS & Neurological Disorders - Drug Targets 22:1, pages 41-50.
Crossref
Crossref
Vincent Chin-Hung Chen, Jing-Yu Huang, Bor-Show Tzang, Tsai-Ching Hsu & Roger S. McIntyre. (2022) Synergistic Effects of the Combinational Use of Escitalopram Oxalate and 5-Fluorouracil on the Inhibition of Gastric Cancer SNU-1 Cells. International Journal of Molecular Sciences 23:24, pages 16179.
Crossref
Crossref
Pari Faraj, Astrid Hermansen, Espen Molden & Kristine Hole. (2022) Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers. Therapeutic Drug Monitoring 44:6, pages 720-728.
Crossref
Crossref
Seema Mehdi, Kishor Manohar, Atiqulla Shariff, Shahid Ud Din Wani, Mansour Almuqbil, Sultan Alshehri, Faiyaz Shakeel, Mohammad T. Imam & Kamsagara L. Krishna. (2022) Analysis of Antidepressants Utilization for Patients Visiting Psychiatric Out-Patient Clinic in a Tertiary Care Hospital. Healthcare 10:10, pages 2081.
Crossref
Crossref
Camila Salvador Sestario, Viviane de Fátima Mestre, Caio Cezar Nantes Martins, Aline Campos Zeffa, Márjori Frítola & Maria José Sparça Salles. (2022) Congenital anomalies and spontaneous abortion in mice resulting from the use of escitalopram. Reproduction, Fertility and Development 34:17, pages 1099-1106.
Crossref
Crossref
Li-Jeng Chen, Tsai-Ching Hsu, Hsiang-Lin Chan, Chiao-Fan Lin, Jing-Yu Huang, Robert Stewart, Bor-Show Tzang & Vincent Chin-Hung Chen. (2022) Protective Effect of Escitalopram on Hepatocellular Carcinoma by Inducing Autophagy. International Journal of Molecular Sciences 23:16, pages 9247.
Crossref
Crossref
Ashwin Kumar N, Gowri Annasamy, Pavani Rekulapally, Suresh S N & Saravanan Krishnan. 2022. Applications of Nanotechnology in Drug Discovery and Delivery. Applications of Nanotechnology in Drug Discovery and Delivery
255
289
.
Tatiyana Mandal, Laxminarayana Kurady Bairy, Podila Satya Venkata Narasimha Sharma & Vijaya Lakshmi Valaparla. (2021) Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 57:1.
Crossref
Crossref
Mahmoud S. Abdallah, Ahmed N. Ramadan, Hend Omara‐Reda, Noha O. Mansour, Mohamed A. Elsokary, Hozaifa K. Elsawah, Shimaa Abdelsattar Zaki, Hend E. Abo Mansour & Esraa M. Mosalam. (2021) Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. CNS Neuroscience & Therapeutics 27:12, pages 1540-1548.
Crossref
Crossref
Manal E. Alkahtani, Alhassan H. Aodah, Omar A. Abu Asab, Abdul W. Basit, Mine Orlu & Essam A. Tawfik. (2021) Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder. Pharmaceutics 13:6, pages 891.
Crossref
Crossref
Madhavi Kodali, Srikanth Lella, Sarath Bodepudi, Therissa Benerji & Krishna Mohan Parvathaneni. (2021) Effectiveness and side-effect profile of Vilazodone and Escitalopram in major Depressive Disorder – An observational study. IP Indian Journal of Neurosciences 7:1, pages 20-25.
Crossref
Crossref
Lamiaa A. Ahmed, Nesma A. Shiha & Amina S. Attia. (2020) Escitalopram Ameliorates Cardiomyopathy in Type 2 Diabetic Rats via Modulation of Receptor for Advanced Glycation End Products and Its Downstream Signaling Cascades. Frontiers in Pharmacology 11.
Crossref
Crossref
Hisayuki Erabi, Go Okada, Chiyo Shibasaki, Daiki Setoyama, Dongchon Kang, Masahiro Takamura, Atsuo Yoshino, Manabu Fuchikami, Akiko Kurata, Takahiro A. Kato, Shigeto Yamawaki & Yasumasa Okamoto. (2020) Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis. Scientific Reports 10:1.
Crossref
Crossref
军祥 武. (2019) Effect of Repeated Transcranial Magnetic Stimulation Combined with Oxalate Aisixitaipulan on Depression and Sleep Disturbance after Stroke. Advances in Clinical Medicine 09:01, pages 37-41.
Crossref
Crossref
Anna Haduch, Marta Rysz, Mariusz Papp & Władysława A. Daniel. (2018) The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat. Biochemical Pharmacology 156, pages 398-405.
Crossref
Crossref
Shoko TsuchimineShinichiro OchiMisuzu Tajiri, Yutaro Suzuki, Norio SugawaraYoshimasa InoueNorio Yasui-Furukori. (2018) Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression. Therapeutic Drug Monitoring 40:3, pages 356-361.
Crossref
Crossref
I YuanChi‑Ting HorngVincent ChenChun‑Hung ChenLi‑Jeng ChenTsai‑Ching HsuBor‑Show Tzang. (2017) Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells. Oncology Letters.
Crossref
Crossref
Vincent Chin-Hung Chen, Yi-Hsien Hsieh, Li-Jeng Chen, Tsai-Ching Hsu & Bor-Show Tzang. (2017) Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. Journal of Cellular and Molecular Medicine.
Crossref
Crossref
Tianmei Si, Gang Wang, Fude Yang, Yiru Fang, Maosheng Fang, Jijun Li, Jicheng Dong, Xinhua Shen, Jianmin Zhuo, Qing Rui, Jinan Wang & Hu Cuili. (2017) Efficacy and safety of escitalopram in treatment of severe depression in Chinese population. Metabolic Brain Disease 32:3, pages 891-901.
Crossref
Crossref
Anna Morozova, Eugene Zubkov, Tatyana Strekalova, Zurab Kekelidze, Zinaida Storozeva, Careen A. Schroeter, Nataliia Bazhenova, Klaus-Peter Lesch, Brandon H. Cline & Vladimir Chekhonin. (2016) Ultrasound of alternating frequencies and variable emotional impact evokes depressive syndrome in mice and rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 68, pages 52-63.
Crossref
Crossref
Wataru Yamadera, Michiaki Morita, Satoshi Sakamoto, Ayako Kuroda, Hiroshi Itoh & Kazuhiko Nakayama. (2016) Comparison of escitalopram alone and combined with zolpidem in treating major depression and related sleep impairments. Sleep and Biological Rhythms 14:3, pages 303-308.
Crossref
Crossref
Yun-Ai Su, Ji-Tao Li, Wen-Ji Dai, Xue-Mei Liao, Li-Cai Dong, Tian-Lan Lu, Chad Bousman & Tian-Mei Si. (2016) Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment. International Clinical Psychopharmacology 31:3, pages 127-133.
Crossref
Crossref
Norio Yasui-Furukori, Kojiro Hashimoto, Shoko Tsuchimine, Tetsu Tomita, Norio Sugawara, Masamichi Ishioka & Kazuhiko Nakamura. (2016) Characteristics of Escitalopram Discontinuation Syndrome. Clinical Neuropharmacology 39:3, pages 125-127.
Crossref
Crossref
Ryosuke Arakawa, Amane Tateno, WooChan Kim, Takeshi Sakayori, Kohei Ogawa & Yoshiro Okubo. (2016) Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [11C]DASB. Psychiatry Research: Neuroimaging 251, pages 1-6.
Crossref
Crossref
Woo-Young JungSae-Heon JangSung-Gon KimYoung-Myo JaeBo-Geum KongHo-Chan KimByeong-Moo ChoeJeong-Gee KimChoong-Rak Kim. (2016) Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder. Psychiatry Investigation 13:4, pages 440.
Crossref
Crossref
Juan F. Codocedo & Nibaldo C. Inestrosa. (2016) Environmental control of microRNAs in the nervous system: Implications in plasticity and behavior. Neuroscience & Biobehavioral Reviews 60, pages 121-138.
Crossref
Crossref
Eiji Kirino. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
465
476
.
Xiao-Li Li, Yong-Gui Yuan, Hua Xu, Di Wu, Wei-Gang Gong, Lei-Yu Geng, Fang-Fang Wu, Hao Tang, Lin Xu & Zhi-Jun Zhang. (2015) Changed Synaptic Plasticity in Neural Circuits of Depressive-Like and Escitalopram-Treated Rats. International Journal of Neuropsychopharmacology 18:10, pages pyv046.
Crossref
Crossref
Angelos Halaris, Aye-Mu Myint, Vidushi Savant, Edwin Meresh, Edwin Lim, Gilles Guillemin, Debra Hoppensteadt, Jawed Fareed & James Sinacore. (2015) Does escitalopram reduce neurotoxicity in major depression?. Journal of Psychiatric Research 66-67, pages 118-126.
Crossref
Crossref
Yingying Kumar, Simon Kung & Gen Shinozaki. (2014) CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. Journal of Psychopharmacology 28:12, pages 1143-1148.
Crossref
Crossref
Cristina Benatti, Silvia Alboni, Joan M.C. Blom, Francesco Gandolfi, Julien Mendlewicz, Nicoletta Brunello & Fabio Tascedda. (2014) Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression. Behavioural Brain Research 272, pages 121-130.
Crossref
Crossref
James R. Thomas, Patrick C. Gedeon & Jeffry D. Madura. (2014) Structural dynamics of the monoamine transporter homolog LeuT from accelerated conformational sampling and channel analysis. Proteins: Structure, Function, and Bioinformatics 82:10, pages 2289-2302.
Crossref
Crossref
Yong-Gu Kim, Hun-Soo Chang, Eun-Soo Won, Byung-Joo Ham & Min-Soo Lee. (2014) Serotonin-Related Polymorphisms in TPH1 and HTR5A Genes Are Not Associated with Escitalopram Treatment Response in Korean Patients with Major Depression. Neuropsychobiology 69:4, pages 210-219.
Crossref
Crossref
Celal Katı, Sevdegul Karadas, Mehmet Aslan, Hayriye Gonullu, Latif Duran & Halit Demir. (2013) Serum Paraoxonase and Arylesterase Activities and Oxidative Stress Levels in Patients with SSRI Intoxication. The Journal of Membrane Biology 247:1, pages 17-21.
Crossref
Crossref
Modar Kassan, George F. Lasker, Suresh C. Sikka, Sree Harsha Mandava, Ahmet Gokce, Khalid Matrougui, Wayne J.G. Hellstrom, Philip J. Kadowitz & Ege Can Serefoglu. (2013) Chronic Escitalopram Treatment Induces Erectile Dysfunction by Decreasing Nitric Oxide Bioavailability Mediated by Increased Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activity and Reactive Oxygen Species Production. Urology 82:5, pages 1188.e1-1188.e7.
Crossref
Crossref
Min Li, Zongbi Bao, Baogen Su, Huabin Xing, Yiwen Yang & Qilong Ren. (2013) Enantiomeric separation of citalopram base by supercritical fluid chromatography. Journal of Separation Science 36:18, pages 3093-3100.
Crossref
Crossref